Mayumi Kobayashi Kato1, Mayu Yunokawa2,3, Seiko Bun4, Tatsunori Shimoi5, Kan Yonemori5, Naoyuki Miyasaka6, Tomoyasu Kato1, Kenji Tamura5. 1. Department of Gynecology, National Cancer Center Hospital, Tokyo, Japan. 2. Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan. mayu.yunokawa@jfcr.or.jp. 3. Department of Medical Oncology/Gynecologic Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo, 135-8550, Japan. mayu.yunokawa@jfcr.or.jp. 4. Department of Pharmacy, National Cancer Center Hospital, Tokyo, Japan. 5. Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan. 6. Department of Perinatal and Women's Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
Abstract
BACKGROUND/ OBJECTIVE: Elderly patients with cancer are often at risk for undertreatment because of frailty, an aging-specific problem. However, current real-world conditions of recurrent ovarian cancer treatment in elderly patients remain unclear. This study aimed to clarify treatment patterns in elderly patients with recurrent ovarian cancer. PATIENTS AND METHODS: We used an ovarian cancer database containing the diagnosis and initial therapy of all patients at the National Cancer Center Hospital in Japan from 2007 to 2014. Patients were stratified into the platinum-sensitive group and the platinum-resistant group. We retrospectively assessed chemotherapy use in patients aged ≤ 64, 65-69, 70-74, 75-79, and ≥ 80 years. RESULTS: Among 253 patients (sensitive group: 135; resistant group: 118), by age group 91%, 95%, 100%, 100%, and 100% received chemotherapy in the sensitive group, and 79%, 67%, 50%, 29%, 0% received chemotherapy in the resistant group, respectively. In the resistant group, the percentage of patients aged 70-74 or 75-79 years who received chemotherapy was significantly lower than the percentage among patients aged ≤ 64 years, respectively (p = 0.01, p = 0.01). In multivariate analysis, age ≥ 70 years (odds ratio [OR], 4.412; 95% confidence interval (CI), 1.628-11.959; p = 0.004) and platinum-free interval < 3 months (OR, 3.434; 95% CI, 1.401-8.399; p = 0.007) were inversely associated with chemotherapy use. CONCLUSIONS: Doctors and patients did not consider chemotherapy in patients aged ≥ 70 years with platinum-resistant disease. Older age was independently and inversely associated with chemotherapy use in platinum-resistant ovarian cancer. Our results highlight the importance of demographic information in clinical decision-making for elderly patients.
BACKGROUND/ OBJECTIVE: Elderly patients with cancer are often at risk for undertreatment because of frailty, an aging-specific problem. However, current real-world conditions of recurrent ovarian cancer treatment in elderly patients remain unclear. This study aimed to clarify treatment patterns in elderly patients with recurrent ovarian cancer. PATIENTS AND METHODS: We used an ovarian cancer database containing the diagnosis and initial therapy of all patients at the National Cancer Center Hospital in Japan from 2007 to 2014. Patients were stratified into the platinum-sensitive group and the platinum-resistant group. We retrospectively assessed chemotherapy use in patients aged ≤ 64, 65-69, 70-74, 75-79, and ≥ 80 years. RESULTS: Among 253 patients (sensitive group: 135; resistant group: 118), by age group 91%, 95%, 100%, 100%, and 100% received chemotherapy in the sensitive group, and 79%, 67%, 50%, 29%, 0% received chemotherapy in the resistant group, respectively. In the resistant group, the percentage of patients aged 70-74 or 75-79 years who received chemotherapy was significantly lower than the percentage among patients aged ≤ 64 years, respectively (p = 0.01, p = 0.01). In multivariate analysis, age ≥ 70 years (odds ratio [OR], 4.412; 95% confidence interval (CI), 1.628-11.959; p = 0.004) and platinum-free interval < 3 months (OR, 3.434; 95% CI, 1.401-8.399; p = 0.007) were inversely associated with chemotherapy use. CONCLUSIONS: Doctors and patients did not consider chemotherapy in patients aged ≥ 70 years with platinum-resistant disease. Older age was independently and inversely associated with chemotherapy use in platinum-resistant ovarian cancer. Our results highlight the importance of demographic information in clinical decision-making for elderly patients.
Authors: Timothy J Perren; Ann Marie Swart; Jacobus Pfisterer; Jonathan A Ledermann; Eric Pujade-Lauraine; Gunnar Kristensen; Mark S Carey; Philip Beale; Andrés Cervantes; Christian Kurzeder; Andreas du Bois; Jalid Sehouli; Rainer Kimmig; Anne Stähle; Fiona Collinson; Sharadah Essapen; Charlie Gourley; Alain Lortholary; Frédéric Selle; Mansoor R Mirza; Arto Leminen; Marie Plante; Dan Stark; Wendi Qian; Mahesh K B Parmar; Amit M Oza Journal: N Engl J Med Date: 2011-12-29 Impact factor: 91.245
Authors: C Falandry; B Weber; A-M Savoye; F Tinquaut; O Tredan; E Sevin; L Stefani; F Savinelli; M Atlassi; J Salvat; E Pujade-Lauraine; G Freyer Journal: Ann Oncol Date: 2013-09-22 Impact factor: 32.976
Authors: Felicia T Roncolato; Dominique Berton-Rigaud; Rachel O'Connell; Anne Lanceley; Jalid Sehouli; Luke Buizen; Aikou Okamoto; Eriko Aotani; Domenica Lorusso; Paul Donnellan; Amit Oza; Elisabeth Avall-Lundqvist; Jonathan Berek; Felix Hilpert; Jonathan A Ledermann; Marie Christine Kaminsky; Martin R Stockler; Madeleine T King; Michael Friedlander Journal: Gynecol Oncol Date: 2017-10-26 Impact factor: 5.482